Viridian shareholders approve 2M share increase to 2016 Equity Plan at annual meeting

Viridian Therapeutics, Inc.\DE

Stockholders approved amendment to 2016 Equity Incentive Plan, increasing share reserve by 2,000,000 shares.
Elected Tomas Kiselak and Jennifer K. Moses as Class II directors to serve until 2026.
Ratified KPMG as independent auditor for 2023 with 39,588,463 votes for.
Advisory vote on NEO compensation passed with 22,946,964 for and 12,351,317 against.
Total shares outstanding as of record date: 43,108,897.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Viridian Therapeutics, Inc.\DE shareholders approved Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders.

Proposal: director election
Outcome: passed

Exact text from the filing

1. Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 26,435,249 8,884,876 4,287,967 Jennifer K. Moses 34,979,960 340,165 4,287,967

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Viridian Therapeutics, Inc.\DE shareholders approved Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder.

Proposal: equity plan
Outcome: passed

Exact text from the filing

4. Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder: For Against Abstentions Broker Non-Votes 22,896,437 12,404,022 19,666 4,287,967

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Viridian Therapeutics, Inc.\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023.

Proposal: auditor ratification
Outcome: passed

Exact text from the filing

2. Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023: For Against Abstentions Broker Non-Votes 39,588,463 9,049 10,580 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Viridian Therapeutics, Inc.\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers.

Proposal: say on pay
Outcome: passed

Exact text from the filing

3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 22,946,964 12,351,317 21,844 4,287,967

View on SEC.gov

448 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-169038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.